Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Bliss GVS Pharma
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 185 | 160 | 212 | 201 | 198 | 184 | 218 | 210 | 198 | 207 | 244 | 218 | 257 |
| Expenses + | 179 | 135 | 158 | 157 | 170 | 149 | 176 | 181 | 177 | 166 | 201 | 183 | 213 |
| Operating Profit | 6 | 24 | 54 | 44 | 28 | 34 | 41 | 30 | 21 | 41 | 43 | 35 | 44 |
| OPM % | 3% | 15% | 26% | 22% | 14% | 19% | 19% | 14% | 11% | 20% | 18% | 16% | 17% |
| Other Income + | 3 | 5 | 13 | 5 | -24 | 4 | 5 | 15 | 12 | 35 | 8 | 16 | 11 |
| Interest | 5 | 1 | 1 | 2 | 2 | 2 | 4 | 1 | 2 | 5 | 3 | 1 | 2 |
| Depreciation | 5 | 6 | 6 | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 8 | 8 | 9 |
| Profit before tax | -1 | 22 | 59 | 40 | -4 | 30 | 36 | 36 | 23 | 63 | 41 | 41 | 45 |
| Tax % | -561% | 34% | 27% | 27% | 24% | 26% | 28% | 29% | 29% | 30% | 30% | 39% | 18% |
| Net Profit + | 3 | 14 | 43 | 29 | -5 | 22 | 26 | 26 | 17 | 44 | 29 | 25 | 37 |
| EPS in Rs | 0.32 | 1.41 | 4.05 | 2.64 | -0.87 | 1.97 | 2.31 | 2.26 | 1.47 | 4.08 | 2.58 | 2.20 | 3.36 |
Financials of Bliss GVS Pharma
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 407 | 547 | 798 | 815 | 899 | 689 | 577 | 747 | 752 | 770 | 810 | 927 |
| Expenses + | 304 | 391 | 596 | 618 | 739 | 566 | 471 | 629 | 634 | 620 | 683 | 763 |
| Operating Profit | 103 | 156 | 203 | 197 | 160 | 123 | 107 | 118 | 117 | 151 | 127 | 164 |
| OPM % | 25% | 29% | 25% | 24% | 18% | 18% | 18% | 16% | 16% | 20% | 16% | 18% |
| Other Income + | 20 | 24 | 12 | -8 | 35 | 26 | 20 | -42 | 18 | -0 | 36 | 71 |
| Interest | 16 | 19 | 20 | 23 | 4 | 8 | 6 | 5 | 10 | 7 | 8 | 12 |
| Depreciation | 11 | 13 | 20 | 21 | 9 | 13 | 17 | 17 | 19 | 26 | 29 | 33 |
| Profit before tax | 96 | 148 | 175 | 145 | 182 | 129 | 104 | 54 | 106 | 117 | 126 | 190 |
| Tax % | 36% | 32% | 36% | 39% | 30% | 26% | 29% | 57% | 28% | 30% | 28% | 29% |
| Net Profit + | 61 | 100 | 113 | 89 | 127 | 95 | 74 | 23 | 77 | 82 | 90 | 135 |
| EPS in Rs | 5.81 | 8.00 | 7.95 | 5.70 | 11.99 | 9.43 | 6.64 | 1.45 | 6.80 | 7.21 | 8.00 | 12.21 |
| Dividend Payout % | 12% | 6% | 8% | 18% | 8% | 5% | 8% | 34% | 7% | 7% | 6% | 8% |
Financials of Bliss GVS Pharma
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 | 11 |
| Reserves | 327 | 402 | 476 | 526 | 636 | 725 | 798 | 808 | 873 | 957 | 1,040 | 1,182 |
| Borrowings + | 160 | 132 | 225 | 118 | 102 | 126 | 122 | 109 | 102 | 100 | 88 | 22 |
| Other Liabilities + | 166 | 218 | 311 | 206 | 157 | 168 | 147 | 181 | 171 | 145 | 162 | 278 |
| Total Liabilities | 662 | 762 | 1,023 | 860 | 905 | 1,030 | 1,077 | 1,109 | 1,157 | 1,212 | 1,301 | 1,492 |
| Fixed Assets + | 234 | 225 | 305 | 143 | 146 | 242 | 234 | 281 | 379 | 370 | 406 | 459 |
| CWIP | 0 | 9 | 4 | 0 | 47 | 0 | 2 | 22 | 3 | 8 | 21 | 6 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 8 | 4 | 4 | 5 |
| Other Assets + | 428 | 527 | 714 | 717 | 712 | 788 | 840 | 803 | 768 | 830 | 870 | 1,022 |
| Total Assets | 662 | 762 | 1,023 | 860 | 905 | 1,030 | 1,077 | 1,109 | 1,157 | 1,212 | 1,301 | 1,492 |
Financials of Bliss GVS Pharma
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 38 | 113 | 289 | 18 | 40 | 47 | 64 | 135 | 34 | 103 | 106 | 139 |
| Cash from Investing Activity + | -29 | -50 | -249 | 48 | -79 | -40 | -45 | -103 | -6 | -83 | -75 | -38 |
| Cash from Financing Activity + | -42 | -40 | -10 | -76 | 17 | -6 | -21 | -24 | -25 | -21 | -30 | -89 |
| Net Cash Flow | -34 | 23 | 30 | -10 | -22 | 0 | -2 | 9 | 3 | -1 | 0 | 11 |
| Free Cash Flow | 5 | 101 | 186 | -7 | 2 | -12 | 55 | 63 | -59 | 75 | 33 | 85 |
| CFO/OP | 45% | 101% | 160% | 29% | -8% | 69% | 87% | 143% | 67% | 91% | 113% | 110% |
Financials of Bliss GVS Pharma
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 222 | 201 | 116 | 134 | 187 | 290 | 293 | 192 | 187 | 192 | 198 | 204 |
| Inventory Days | 69 | 55 | 50 | 55 | 46 | 64 | 110 | 116 | 94 | 113 | 111 | 129 |
| Days Payable | 165 | 153 | 100 | 55 | 47 | 75 | 82 | 86 | 79 | 58 | 63 | 89 |
| Cash Conversion Cycle | 126 | 102 | 67 | 134 | 186 | 279 | 321 | 221 | 202 | 247 | 246 | 244 |
| Working Capital Days | 105 | 84 | -10 | 135 | 154 | 232 | 264 | 179 | 192 | 207 | 199 | 214 |
| ROCE % | 23% | 31% | 29% | 27% | 26% | 18% | 12% | 14% | 12% | 14% | 12% | 17% |
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…